HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 9, September 2016 – Infectious Diseases       » Curcumin Derivatives May Prevent Alzheimer's Disease by Promoting Amyloid- Clearance       » Varian Chosen to Equip First Government Owned Proton Centre in China       » Medtronic and SingHealth Collaborate on a Centre of Excellence to Fight Diabetes       » NCCS Awards Contract for Proton Beam Therapy System to Hitachi Asia      
INSIDE INDUSTRY
Amorfix enters into agreement with a major global pharmaceutical company for Alzheimer's disease diagnostic
Amorfix Life Sciences Ltd., an early-stage product development company developing therapeutic antibodies and diagnostics targeting misfolded protein diseases, has signed an agreement with a major global pharmaceutical company to use the human Alzheimer's disease diagnostic assay in phase 1 clinical studies.

Amorfix has granted its collaborator access to its proprietary EP-AD assay technology and the Company will complete assay optimization and validation prior to using the assay as part of a clinical trial to investigate the effects of a novel therapeutic for the treatment of Alzheimer's disease. The terms of the agreement have not been disclosed.

"We are very excited to be working with a world-class pharmaceutical company with the resources and expertise to assist in the further development our human Alzheimer's disease diagnostic assay technology. The Company has worked very hard to create a diagnostic test that can identify patients with early-stage disease and we are gratified to have the opportunity to assist in the clinical development of new therapeutics that may offer improved treatment options for Alzheimer's disease patients" said Dr. Robert Gundel, Amorfix President and CEO. "In addition, this agreement is an example of our business plan to establish effective partnerships and strategic alliances with companies that have the resources and expertise to help advance our products to clinical development and commercialization".

The EP-AD diagnostic assay is capable of identifying early-stage Alzheimer's disease patients and patients with mild cognitive impairment (MCI) who are at high risk of developing Alzheimer's disease. The EP-AD assay measures levels of Abeta aggregates, a known biomarker of Alzheimer's disease, and can also be used to monitor the effects of Alzheimer's disease treatments on Abeta aggregates, the building blocks of plaques that form in the brains of people with Alzheimer's disease.
information, future events or otherwise.

Click here for the complete issue.

NEWS CRUNCH  
news Enterprise meets technology: More than 300 enabling innovations showcased at TechInnovation
news CPhI's Pre-Connect Congress outlines current trends in pharma
news World Population Day 2016
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Big Data in Healthcare
December:
Orthopaedics
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy